Skip to main content
. Author manuscript; available in PMC: 2024 Apr 30.
Published in final edited form as: Curr Opin Virol. 2022 Sep 27;56:101260. doi: 10.1016/j.coviro.2022.101260

Table 2.

Selection of cell-based immunotherapy trials for EBV-associated diseases

NIH Clinical Trials Identifier Intervention Platform Dose and route application Outcome measures Results Status as of January, 2022
NCT03648697 Adoptive T-cell immunotherapy LMP1, LMP2, and EBNA1-TCR-T cells 1 dose, i.v. NPC Adverse events, clinical pending Recruiting
NCT03925896 Adoptive T-cell immunotherapy LMP2 specific TCR-T cells 1 dose, i.v. NPC Maximum Tolerated Dose pending Recruiting
NCT00430534 Adoptive T-cell immunotherapy gemcitabine-carboplatin followed by EBV-specific CTL Multiple doses gemcitabine-carboplatin, Followed by 4 doses of EBV-specific CTL NPC Survival, disease progression pending Active (Phase III)
NCT01498484 Adoptive T-cell immunotherapy EBV specific CTLs from HLA matched donor (ATA129) 3 doses, i.v. lymphoma Clinical response rate Complete or partial remission in over 58% Completed (Phase II; Prockop, 2020)
NCT03283826 Adoptive T-cell immunotherapy EBV specific CTLs from HLA matched donor (ATA129) 3 doses, i.v. MS Adverse events, clinical progression (EDSS), MRI, IgG Index pending Recruiting